Genmab A/S (OTCMKTS:GNMSF) Stock Short Interest Falls 44.4%

Genmab A/S (OTCMKTS:GNMSF) saw a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 106,477 shares, a decline of 44.4% from the September 15th total of 191,429 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 359 shares, the short-interest ratio is presently 296.6 days.

Genmab A/S Stock Performance

Shares of OTCMKTS GNMSF remained flat at $367.00 during midday trading on Friday. Genmab A/S has a one year low of $232.34 and a one year high of $396.97. The company has a market capitalization of $22.60 billion, a PE ratio of 28.78 and a beta of 0.75. The stock’s 50 day moving average is $342.32 and its two-hundred day moving average is $294.43. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Genmab A/S Company Profile

Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.

Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies.